Novel fluorescent compounds for labelling tumour tissue
Patent Information
- Application Number
- IN202217071734
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-05-15
- Filing Date
- 2022-12-12
- Publication Date
- 2026-10-27
- Estimated Expiration
- 2041-05-12
AI Technical Summary
Existing fluorescent markers for tumor labeling have limited persistence and accumulation in tumor tissues, leading to poor visualization and incomplete tumor detection during surgical procedures, requiring coupling with targeting molecules and offering low signal/noise ratios due to short duration and inadequate distribution.
Development of fluorescent compounds with specific affinity for tumor tissues, allowing direct use without coupling, providing prolonged persistence in tumors for up to several days and improved visualization by preferentially accumulating in tumor tissues while being eliminated from healthy tissues.
The compounds achieve enhanced tumor visualization and specificity, enabling more effective surgical interventions by maintaining a high signal/noise ratio for extended periods, facilitating better tumor delineation and complete resection.
Abstract
Description
Technical field[2] Labeling of tumor tissue with fluorescent compounds is of considerableinterest in the field of medical imaging, because among other things it allows thelocalization of tumors.Prior art[3] Fluorescent compounds have been used for more than fifty years inmedicine as markers in noninvasive imaging techniques for surveillance and / ordiagnosis.Technical problem[4] The emergence of new fluorescent imaging technologies in the service ofsurgery, requiring improved sensitivity and accuracy, leads to research for newfluorescent molecules giving better and better performance.[5] In the context of diseases such as cancer, it is necessary in particular tohave a preferential distribution of the fluorescent molecules in the tumor tissuesrelative to the healthy tissues, as well as sufficiently long persistence of thefluorescence to allow improved specificity of labeling and to supply an aid forsurgical intervention, for example to delimit the regions of tumors to be removed.[6] Certain existing fluorescent markers have limited persistence offluorescence, which necessitates operating on the patient soon after injection ofthe marker and does not allow a satisfactory delimitation of the tumor tissue to beobtained. In other cases, there is insufficient accumulation of the marker in thetissues, which leads to poor labeling and therefore problems in detection. Thelocalization of lesions or of tumors and then their removal for example by surgeryis then incomplete.[7] Another problem with the existing fluorescent markers, in particularindocyanine green (ICG), which is one of the few dyes used for labeling tumorsduring a surgical procedure, is the need for the presence of tumoralneovascularization to obtain labeling of the tumor tissue. Moreover, indocyaninegreen, like the other existing dyes in the prior art, is only visible in tumor tissues upto 24h after its injection. This short duration does not give good elimination of thecirculating dye outside of the tumor tissues, which causes poor visualization as thesignal / noise ratio is low.[8] Another major drawback of the existing compounds is that they cannot beused directly. In fact, in order to be used they need to be coupled with othertargeting molecules such as antibodies, proteins, molecules specific to the tumortissue, folic acid, or steroids.[9] The present invention allows us to overcome the problems of the prior artexplained above by supplying fluorescent molecules having preferentialdistribution in the tumor tissues relative to the healthy tissues and sufficientpersistence for use thereof in imaging techniques for monitoring, diagnosis, and / oras an aid in surgery. These new molecules have the major advantage that theycan be used alone and directly, without prior coupling, owing to their specificaffinity for tumor tissue. Moreover, relative to the molecules of the prior art, theyremain in the tumor tissues much longer, for up to several days, which allowsmore thorough elimination of these fluorescent molecules circulating outside of thetumor tissues, and thus improved visualization owing to a better signal / noise ratio.Summary of the invention
[10] The present invention relates to a compound of formula (I)[Chem. 1](I)in whichn1 and n2 are each an integer from 0 to 15,R1, R2, R3, R4, R5 and R6 are each selected independently from H, OH, SH, NH2,SO3R10 and X-R11-Y,R10, R'10 being independently H, Na or K,X, X', X'' being independently O, S or NH,R11, R'11, R''11 being selected independently from C1 to C15 alkyl, aryl, heteroaryl,(C1 to C15 alkyl)aryl, (C1 to C15 alkyl)heteroaryl, aryl(C1 to C15 alkyl) andheteroaryl(C1 to C15 alkyl);Y, Y', Y'' being selected independently from H, halogen, COOR'10 or amide;R7 and R8 each being selected from H, OH, SH, NH2, C1 to C15 alkyl, and X'-R'11-Y';R9 being selected from H, OH, SH, NH2 and X''-R''11-Y'',said compound comprising at least one group X-R11-Y, X'-R'11-Y' or X''-R''11-Y''with Y, Y', and / or Y'' which is COOR'10.
[11] The present invention also relates to the method of preparation of thecompounds of formula (I) according to the invention, as well as the method forlabeling tumor tissue with one of the compounds according to the invention orprepared according to the method of the invention.Disclosure of the invention
[12] The present invention relates firstly to a compound of formula (I)[Chem. 2](I)in whichn1 and n2 are each an integer from 0 to 15,R1, R2, R3, R4, R5 and R6 are each selected independently from H, OH, SH, NH2,SO3R10 and X-R11-Y,R10, R'10 being independently H, Na or K,X, X', X'' being independently O, S or NH,R11, R'11, R''11 being selected independently from C1 to C15 alkyl, aryl, heteroaryl,(C1 to C15 alkyl)aryl, (C1 to C15 alkyl)heteroaryl, aryl(C1 to C15 alkyl) andheteroaryl(C1 to C15 alkyl);Y, Y', Y'' being selected independently from H, halogen, COOR'10 or amide;R7 and R8 each being selected from H, OH, SH, NH2, C1 to C15 alkyl, and X'-R'11-Y';R9 being selected from H, OH, SH, NH2 and X''-R''11-Y'',said compound comprising at least one group X-R11-Y, X'-R'11-Y' or X''-R''11-Y''with Y, Y', and / or Y'' which is COOR'10.
[13] In the sense of the present invention, "C1 to C15 alkyl" means a cyclic,linear, or branched hydrocarbon chain containing from 1 to 15 carbon atoms,preferably from 2 to 6 carbon atoms and even more preferably from 4 to 6 carbonatoms, in particular 5 carbon atoms and that may in particular be a methyl, ethyl,n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl,2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, isopentyl, neopentyl, 2-pentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, heptyl, octyl, nonyl, decyl, dodecyl,or palmityl chain.
[14] In the sense of the present invention, "aryl" means an aromatic group,containing one or more aromatic rings, optionally substituted.
[15] In the sense of the present invention, "heteroaryl" means an aromaticgroup, containing one or more aromatic rings, optionally substituted, andcomprising at least one heteroatom different than carbon and hydrogen.
[16] In the sense of the present invention, "aralkyl" means an aryl groupsubstituted with one or more alkyl groups; said alkyl groups may be C1 to C15 alkylgroups, preferably containing from 1 to 15 carbon atoms.
[17] In the sense of the present invention, "heteroaralkyl" means a heteroarylgroup substituted with one or more alkyl groups; said alkyl groups may be C1 toC15 alkyl groups, preferably containing from 1 to 15 carbon atoms.
[18] According to a particular embodiment, in the above formula, n1 or n2 are,independently of one another, equal to 1, 2, 3, 4 or 5, even more preferably 3 or 4.
[19] According to another particular embodiment, in the above formula n1=n2and is preferably equal to 1, 2, 3, 4 or 5, even more preferably 3 or 4.
[20] According to another particular embodiment, the molecule is symmetric. Inthis case, it comprises a single group X''-R''11-Y'' with Y'' which is COOR'10 that iscarried by R9 and / or 2 groups X-R11-Y with Y which is COOR'10, one carried byone of R1, R2, R3 or R7, preferably one of R1, R2 or R3 and the other carried by oneof R4, R5, R6 or R8, preferably one of R4, R5 or R6.
[21] According to a particular embodiment, in the above formula, R10, and / orR'10, may be identical. Similarly, X, X', and / or X'' may be identical, Y, Y', and / or Y''may be identical, R11, R'11, and / or R''11 may be identical.
[22] The compounds according to the invention may in particular be selectedfrom the compounds of the following general formula:for which X'' may be O, S or NH, corresponding to the following formulas:
[23] The compounds of formula (I) according to the invention may in particularbe selected from the compounds of formula (I) for which R1, R2, R3, R4, R5 and R6are not all simultaneously H, which excludes in this case the compoundsaccording to the following formula (II):
[24] The compound of formula (I) according to the invention may preferably beselected from the compounds of the following general formulas:[Chem. 3][Chem. 4]in which R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined above.
[25] According to a particular embodiment, the compounds according to theinvention may be selected from the compounds of the following formulas[Chem. 5][Chem. 6][Chem. 7]in which R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined above.
[26] According to a preferred embodiment, the compounds according to theinvention may be selected from the following compounds:[Chem. 8][Chem. 9][Chem. 10][Chem. 11][Chem. 12][Chem. 13][Chem. 14][Chem. 15][Chem. 16]
[27] The present invention relates secondly to the method of preparation of thecompounds of formula (I) according to the invention comprising a reaction stepbetween:[Chem. 17]and[Chem. 18]
[28] This reaction is preferably carried out by heating under reflux in thepresence of sodium acetate in a mixture of acetic acid and acetic anhydride.
[29] The invention relates thirdly to the method for labeling tumor tissue withone of the compounds according to the invention or prepared according to themethod of the invention.
[30] In the sense of the present invention, "tumor tissue" means tissueconsisting of tumor cells, which are abnormal proliferating cells, and of asupporting tissue, also called tumoral stroma or interstitial tissue, composed ofcells and extracellular substance in which the tumoral vascularization is located.
[31] The fluorescent compounds according to the invention have the particularfeature, after they have diffused in the body, of being trapped in tumor tissue,whereas they are eliminated from healthy tissues. This particular feature makes itpossible to use these fluorescent compounds directly, without prior coupling toanother labeling molecule, thus making their use simpler, quicker and moreeffective than that of the compounds of the prior art. It was observed that thiselimination from healthy tissues increases over time. In general, between 24 and72 hours, preferably between 36 and 60 hours and more preferably 48 hours afteradministration of these compounds, their elimination from healthy tissues is total.However, they remain trapped in the tumor tissues. This property gives a cleardifferentiation of tumor tissues relative to healthy tissues and thus thesecompounds can be used in applications of monitoring, diagnosis and / or as an aidto surgery in a context of cancerous diseases. This differentiation lasts for 6 to 48hours, preferably 12 to 36 hours, allowing targeted programming of diagnosis orsurgery.
[32] The compounds according to the invention may thus be used in particularin the context of cancers, for example hormone-dependent cancers, such asbreast cancer or digestive system cancers, such as pancreatic cancer. In fact, inpancreatic cancer, the tumors are particularly difficult to remove completely bysurgery, as they are not easily delimited. The use of the compounds according tothe invention makes it possible to obtain better visualization of the contours of thetumors owing to the differentiation of labeling between tumor tissue and healthytissue, and thus more effective tumor resection by surgery.
[33] The invention also relates to the use of one of the compounds accordingto the invention or prepared according to the method of the invention in a methodfor labeling tumor tissue.
[34] This method of labeling tissues requires administration of the compoundsby the intravenous or intraarterial route, or in another vessel, in particular alymphatic vessel, or by local injection, or by local application, preferably by theintravenous route.
[35] The invention further relates to a composition comprising one of thecompounds according to the invention or prepared according to the method of theinvention and at least one pharmaceutically acceptable adjuvant.
[36] The invention also relates to one of the compounds according to theinvention or prepared according to the method of the invention or a compositioncomprising one of the compounds according to the invention or preparedaccording to the method of the invention for use thereof in a method of labelingand / or detection of tumor tissue, and / or in the surgical treatment of tumors.
[37] The invention also relates to a method for detecting tumor tissuecomprising a step of labeling tumor tissue with one of the compounds according tothe invention or prepared according to the method of the invention, and a step ofdetection by medical fluorescence imaging or fluorescence spectrometry.FiguresFig. 1
[38] [Fig. 1] shows the median values and standard deviations of thetumor / abdomen intensity ratios as a function of time post-injection of compound 2(CJ215) and of ICG.Fig. 2
[39] [Fig. 2] shows the results of ex vivo imaging of pancreatic tumors afterinjection of two compounds according to the invention and of a fluorescent agentof the prior art (ICG).Examples
[40] Example 1:[Chem. 19]Compound (1)A mixture of 4-[(5-carboxypentyl)oxy]-6-sulfo-1-(4-sulfobutyl)-2,3,3-trimethyl20 benz(e)indolium (internal salt and disodium salt) (9 g; 15 mmol), 2-chloro-1-formyl3-(hydroxymethylene)-1-cyclohexene (1.30 g; 7.50 mmol), and sodium acetate(3g; 36.6 mmol) in a 60 / 30 mixture of acetic acid and acetic anhydride is heatedunder reflux for 10 minutes. The reaction mixture is cooled to room temperatureand the precipitate is separated by filtration and washed with diethyl ether to give4.33 g (yield: 43.9%) of a green solid. The crude product is purified by columnflash chromatography (inverse phase silica gel C18, acetonitrile 0-25% / water).
[41] Example 2:[Chem. 20]Compound (2)Sodium methylate (440 mg; 7.6 mmol) is added to compound (1) (1 g; 0.76 mmol)in solution in 500 mL of methanol. The reaction mixture is heated under reflux for16 h and concentrated under vacuum, and then filtered. The residue obtained iswashed with cold methanol and with acetone and dried under vacuum to give450 mg of a green solid (yield: 45%). The crude product is purified by column flashchromatography (inverse phase silica gel C18, acetonitrile 0-25% / water).
[42] Example 3:[Chem. 21]Compound (3)MeSNa (106 mg; 1.5 mmol) is added to compound (1) (400 mg; 0.30 mmol) insolution in 20 mL of a 50 / 50 mixture of methanol / NMP (N-methyl-2-pyrrolidone).The reaction mixture is heated under reflux for 4 h, and then diethyl ether (20 mL)is added to the mixture. The precipitate is filtered and washed with the samesolvent to give 254 mg of crude product (yield: 61%; sulfur odor). The crudeproduct is purified by column flash chromatography (inverse phase silica gel C18,acetonitrile 0-25% / water).
[43] Example 4:[Chem. 22]Compound (4)A mixture of 6-sulfo-1-(4-sulfobutyl)-2,3,3-trimethylbenz(e)indolium (internal saltand DCHA salt) (2 g; 4.7 mmol), 2-chloro-1-formyl-3-(hydroxymethylene)-1-cyclohexene (0.40 g; 2.35 mmol), and sodium acetate (0.9 g; 11 mmol) in a 50 / 20mixture of acetic acid and acetic anhydride is heated under reflux for 15 minutes.The precipitate is separated by filtration, washed with ethanol and acetone anddried under vacuum to give 1.6 g (yield: 63.8%) of a brick-red powder. The crudeproduct is purified by column flash chromatography (inverse phase silica gel C18,acetonitrile 0-25% / water).
[44] Example 5:[Chem. 23]Compound (5)8 mL of 1M methanolic KOH, 16 mL of DMSO and compound (4) (500 mg;0.25 mmol) are added to 3-(4-hydroxyphenyl)propionic acid (660 mg; 4 mmol).The reaction mixture is stirred at room temperature for 8h, and then 150 mL ofethyl acetate is added dropwise. The precipitate is separated by filtration, washedwith ethanol and acetone and dried under vacuum to give 260 mg (yield: 45%) of agreen powder. The crude product is purified by column flash chromatography(inverse phase silica gel C18, acetonitrile 0-25% / water).
[45] Example 6:[Chem. 24]Compound (6)4-Aminohydrocinnamic acid (816 mg; 4.9 mmol), 25 mL of DMSO andtriethylamine (500 mg; 4.9 mmol) are added to compound (4) (520 g; 0.49 mmol).The reaction mixture is stirred at room temperature for 8h, and then 200 mL ofacetone is added dropwise. The precipitate is separated by filtration, washed withacetone and dried under vacuum to give 430 mg (yield: 74%) of a red powder. Thecrude product is purified by column flash chromatography (inverse phase silica gelC18, acetonitrile 0-25% / water).
[46] Example 7:[Chem. 25]Compound (7)1 mL of 1M methanolic KOH, 16 mL of DMSO and compound (4) (500 mg;0.25 mmol) are added to 4-mercaptohydrocinnamic acid (91 mg; 0.5 mmol). Thereaction mixture is stirred at room temperature for 30 minutes, and then 50 mL ofethyl acetate is added dropwise. The precipitate is separated by filtration, washedwith ethanol and acetone and dried under vacuum to give 310 mg (yield: 54%) of agreen powder. The crude product is purified by column flash chromatography(inverse phase silica gel C18, acetonitrile 0-25% / water).
[47] Example 8: Comparison of a compound according to the invention and afluorescent agent of the prior art (ICG) for in vivo imaging of mammary tumorsICG (or indocyanine green / Infracyanine) is a fluorescent agent of the prior art,already approved for use in humans for evaluation of cardiac and hepatic function,as well as in ophthalmology, for retinal diseases. It is also undergoing evaluation inmany clinical trials throughout the world for guidance of surgery during tumoralexereses, or mapping of the ganglia draining the tumors, by near infrared imaging.ICG was compared with compound (2) according to the invention, synthesis ofwhich is described above in example 2; this compound is called CJ215 in thisstudy.The study included 30 mice in total, distributed in three groups. The tumoral graftswere all carried out with 50 000 cells 4T1-Dendra2 / 20 μl injected in 2 mammaryglands contralaterally for each of the mice.
[48] The injections of the biomarkers (compound 2 called CJ215 in this studyand ICG) were carried out on D9 post-tumoral grafting (to limit the appearance ofnecrosis in the tumors).The variation of the intensity of the fluorescence signals recorded for each of thebiomarkers over time was evaluated from the microscopy image. The capacity ofthe two markers for producing a signal specifically localized to the tumor wasassessed quantitatively by calculating the ratio of the specific signal associatedwith the tumor to the nonspecific signal in the surrounding tissues.
[49] The imaging protocol was carried out at times 2h, 24h, 48h, 4 and 6 dayspost-injection for all the mice. All the images made at each acquisition time wereacquired on the IVIS Spectrum imager (Perkin Elmer) with the following parameters:For detection of the GFP form of Dendra2 (detection of the tumor):- Excitation at 465 nm- Emission between 520 and 580 nmFor detection of the biomarkers:- Excitation at 745 nm- Emission between 800 and 840 nmThe quantitative measurements were performed on the raw images, which had notbeen deconvoluted. For the two fluorophors, the acquisition time wasparameterized in automatic mode. In this mode, the system determines theacquisition time taken to reach the stipulated target value (6000 counts) in the timeallowed (fixed at 2 min).
[50] Fig. 1 reports the median values and standard deviations of thetumor / abdomen intensity ratios as a function of time post-injection of CJ215 andICG.Measurement of the ratio of the tumor / abdomen intensities illustrated in this figuremakes it possible to show that:- the intensity ratios are significantly higher for compound 2 (CJ215) compared toICG, regardless of the time post-injection (from 1.5 times at 2h to more than 3times at D+6), which translates into a capacity for identifying a specific signal inthe tumors earlier and more specifically with compound 2 (CJ215). These resultsalso indicate the possibility of very significantly improving the specificity of thesignal to the tumor by increasing the time between injection of compound 2(CJ215) and imaging;- the signal / noise ratio increases continuously for compound 2 (CJ215) up to 6days post-injection, the last day of examination considered in this protocol. At thisstage, ICG is no longer observable in the tumors (starting from 48h). The greatstability of the intratumoral signal of compound 2 (CJ215), compared to thesurrounding tissues, which eliminate the product, thus offers an improved capacityfor identifying the tumors and thus contributes to significant improvement in thefine delimitation of the tumoral margins, which is still problematic with ICG.
[51] Example 9: Comparison of two compounds according to the invention anda fluorescent agent of the prior art (ICG) in ex vivo imaging of pancreatic tumors.A model of orthotopic pancreatic adenocarcinoma in the mouse was developed.The tumoral cells were amplified subcutaneously in SCID mice and the resultantfragments were then implanted surgically in the pancreas of irradiated BALB / cnude mice.The development of the tumor was monitored in vivo by MRI (4.7T, PharmaScan,Bruker Biospin) at three time points, D14, 28 and 36. The animals were subjectedto a weak fluorescence in order to minimize autofluorescence. Fluorescentimaging was performed with a charge-coupled device (CCD) camera (PhotonRT,BiospaceLab) with excitation at 700 nm and an emission filter at 770 nm. After sessions of in vivo imaging performed at 2h, 48h and 164h, ex vivofluorescent images were acquired. The fluorescent compounds according to theinvention 2 (CJ215) and CJ319 (the structure of which is detailed below) wereinjected intravenously at 2 mg / kg, 39 days after implantation of the tumorfragments, whereas the average volumes of the tumors were about 70 mm³.Indocyanine green (ICG), a dye widely used in the per-operative imaging of tumors,was included as a control.[Chem. 26](CJ319)
[52] The ex vivo fluorescence imaging described in Fig. 2 showed that 2 hoursafter injection, the two fluorescent compounds according to the invention werepresent in the pancreas and the tumor in almost equivalent amounts. However, 48hours after injection, a clear preferential distribution was observed for the tumor,both compounds producing a fluorescent signal about four times higher in thetumor than in the surrounding pancreatic tissue. This effect persisted six days afterinjection, although the signal decreased as time passed. In comparison,indocyanine green did not show any specific accumulation in the pancreas or thetumor.These results show the superiority of the compounds of the invention relative to afluorescent agent of the prior art at the level of their specific distribution in a tumortissue.
Claims
1. A compound of formula (I) [Chem. 27] (I) in which n1 and n2 are each an integer from 0 to 15, R1, R2, R3, R4, R5 and R6 are each selected independently from H, OH, SH, NH2, SO3R10 and X-R11-Y, R10 and R'10 being independently H, Na or K, X, X' and X'' being independently O, S or NH, R11, R'11 and R''11 being selected independently from C1 to C15 alkyl, aryl, heteroaryl, (C1 to C15 alkyl)aryl, (C1 to C15 alkyl)heteroaryl, aryl(C1 to C15 alkyl) and heteroaryl(C1 to C15 alkyl); Y, Y' and Y'' being selected independently from H, halogen, COOR'10 or amide; R7 and R8 each being selected independently from H, OH, SH, NH2, C1 to C15 alkyl, and X'-R'11-Y'; R9 being selected from H, OH, SH, NH2 and X''-R''11-Y'', said compound comprising at least one group X-R11-Y, X'-R'11-Y' or X''-R''11-Y'' with Y, Y' and / or Y'' which is COOR'10.
2. The compound as claimed in claim 1 for which R1, R2, R3, R4, R5 and R6 are not all simultaneously H.
3. The compound as claimed in claim 1 or 2 selected from the compounds of the following formulas: [Chem. 28] [Chem. 29] in which R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in claim 1.
4. The compound according to one of the preceding claims selected from the compounds of the following formulas [Chem. 30] [Chem. 31] [Chem. 32] in which R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in claim 1.
5. The compound according to one of the preceding claims selected from the compounds of the following formulas [Chem. 33] [Chem. 34] [Chem. 35] [Chem. 36] [Chem. 37] [Chem. 38] [Chem. 39] [Chem. 40] [Chem. 41]6. A method of preparation of the compounds as claimed in one of claims 1 to 5 comprising a reaction step between: [Chem. 42] and [Chem. 43]7. A method for labeling tumor tissue with one of the compounds as claimed in one of claims 1 to 5 or prepared as claimed in claim 6.
8. The use of one of the compounds as claimed in one of claims 1 to 5 or prepared as claimed in claim 6 in a method for labeling tumor tissue.
9. The compound as claimed in one of claims 1 to 5 or prepared as claimed in claim 6 or a composition comprising the compound as claimed in one of claims 1 to 5 or prepared as claimed in claim 6 for use thereof in a method for labeling and / or detection of tumor tissue, and / or in the surgical treatment of tumors.
10. A method for detecting tumor tissue comprising a step of labeling tumor tissue with one of the compounds as claimed in one of claims 1 to 5 or prepared as claimed in claim 6, and a step of detection by medical fluorescence imaging or fluorescence spectrometry.
